Clinical Trial Update: Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating dabigatran etexilate for prevention of stroke and thromboembolism in atrial fibrillation and atrial flutter.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Atrial Flutter

Drugs mentioned

• Dabigatran etexilate (Dabigatran etexilate)

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Atrial Fibrillation, Atrial Flutter | Phase 4 | Status: COMPLETED | Results posted: 2017-09-12